EuroPCR 2015, the world-leading course in interventional medicine, runs from May 19 – May 22, 2015 at the Palais des Congres in Paris, France.
EuroPCR 2015, the world-leading course in interventional medicine, runs from May 19 – May 22, 2015 at the Palais des Congres in Paris, France. The programme features a mix of breaking news, live case demonstrations, oral abstracts, posters, debates, and tips-and-tricks tutorials in the coronary, structural heart disease, peripheral, hypertension/heart failure, nurse/technician, and multispecialty categories. Results for six novel studies being presented as abstracts at the meeting next week are highlighted herein.
1. The "Radial Paradox": Higher Femoral Access Site Complications Offsets Radial Benefits
Growing acceptance of radial access during cardiac catheterisation to reduce access site complications may contribute to a loss of experience with femoral access, potentially increasing vascular complications when the femoral technique is used. Montreal Heart Institute researchers compared contemporary and historical patient cohorts (n=17,059) and found that vascular access complications today, using the femoral artery approach—used typically as a back-up method—are more common than before radial access was introduced. This, in turn, offsets the benefit of radial access at a population level since patients in the contemporary cohort (radial + femoral) suffered more vascular complications than those in the historical cohort. Trainees and default radial operators should acknowledge the “Campeau Radial Paradox” —named after radial pioneer Lucien Campeau—and take appropriate action, investigators say.
CONTACT: Dr. Lorenzo Azzalini, Montreal Heart Institute and Montreal Health Innovations Coordinating Center, CANADA firstname.lastname@example.org
Date: Wednesday May 20, 10:30, Room Ternes 1 AND Wednesday May 20, 11:08, Room 253*
*As one of the abstracts featured in "PCRs Got Talent,"this presentation may also make it to the second round, Thursday May 16:50-18:20 and final round, Friday 9:00-10:00, both in Room 253.
2. Most Non-Culprit Vessels with Significant Stenosis Not Functionally Important: FFR Study
Controversy exists surrounding the benefits/risks of reopening all significantly blocked ("stenotic") vessels during primary angioplasty for heart attack, or simply reopening the "culprit" blocked artery responsible for the MI and treating the others at a later date, or leaving them be. An ongoing study, COMPARE-ACUTE, is using fractional flow reserve (FFR) technology to assess whether or not a vessel blockage seen on angiography has a functional effect on the heart (by impeding oxygen flow). Preliminary findings from the trial show that more than 50% of non-culprit arteries deemed to have significant stenosis are not functionally significant by FFR, a finding that will no doubt increase the debate as to whether and when to intervene on non-infarct-related arteries.
CONTACT: Dr. Elmir Omerovic, Sahlgrenska University Hospital, Gotheborg, SWEDEN email@example.com (First author Dr. Peter Smits, Maasstad Hosptial, Rotterdam)
Date: Wednesday May 20, 11:00, Room 253 AND Friday May 22, 9:39, Room 242B*
3. Drug-Eluting Stents Best Bare Metal in Elderly Patients, without Bleeding Trade-off
Despite the wide uptake of drug-eluting stents (DES), little research exists supporting their safety and efficacy in elderly patients (>75 years), who are typically excluded from randomised trials. A new study of 635 consecutive, elderly patients at two European centres compared "net" clinical benefits (both ischaemic and bleeding events) among patients who received a DES (170 patients) or a bare metal stent (BMS, 465 patients). Investigators found that duration of antiplatelet therapy, as per treatment guidelines, was longer among the DES-treated patients than the bare metal stent-treated patients, but this did not translate into higher rates of bleeding. Moreover, net benefit was higher in the DES group (40.5%) than in BMS-treated patients (55.7%; p=0.009), driven by a significant reduction in myocardial infarction (8.6 vs. 16.6%; p=0.038) and target vessel revascularisation rates (7.9 vs. 21.9%; p=0.003).
CONTACT: Dr. Fabio Mangiacapra, Campus Bio-Medico University, Rome, ITALYfabio.firstname.lastname@example.org (Lead author: Dr. Giuseppe Di Gioia, Campus Bio-Medico University)
Date: Wednesday May 20, 9:32, Room Arlequin AND Wednesday May 20, 11:04, Room 253*
4. Detailed Analysis of Door to Balloon Time Delays in STEMI Finds Key Areas for Improvement
A seven-year review of 797 STEMI patients at a Melbourne hospital addressing door-to-balloon times (DTBT) in heart attack patients suggest that certain timeframes are more critical than others in reducing the delays to angioplasty that lead to worse outcomes. Key areas for cutting DTBTs down to 90 minutes or less, according to Australian researchers led by nurse Lorelle Martin, include prompt or prehospital performance of the diagnostic ECG and expediting the assembly of the cathlab team, especially in high-risk patients. Specific procedural timeframes were also identified as areas for improvement. Door to ECG time, for example, was identified as a being particularly protracted in female patients. The data also confirmed that patients with DTBT >90 minutes died at nearly three times the rate of patients treated within the recommended 90 minutes.
Contact: Lorelle Martin (nurse), Austin Health, Melbourne, Australia, email@example.com
Date: Wednesday 20th, 11:34, Room 253 AND Thursday May 21, 11:30 Room 251.*
5. Transcatheter Valve Outcomes in Patients with Paradoxical Low-Gradient Aortic Stenosis
Patients with severe aortic stenosis (AS) who have a mean transvalvular aortic gradient (MPG) <40 mmHg due to a reduced stroke volume despite preserved ejection fraction are relatively common, making up more than 40% of patients who underwent transcatheter valve implantation at three independent institutions, new German research shows. This particular patient group with “paradoxical” low-flow, low-gradient disease (PLF-LGAS) tended to be slightly younger, but at higher baseline risk, and typically experienced longer hospital stays. According to researchers, both in-hospital (10.9% vs. 6.7%, p=0.011) and one-year mortality (32.0% vs. 24.1%; p=0.008) were significantly higher in PLF-LGAS patients when compared with the high-gradient aortic stenosis patients.
CONTACT: Prof. Alexander Lauten, University Heart Center Jena, Germany firstname.lastname@example.org
Wednesday May 20, 16:21, Room: Arlequin
6. Carotid Artery Stenting Study Offers Insights into which Patients Benefit Long-term
Prior studies have shown that carotid-artery stenting (CAS) improves three-month neurocognitive function in patients with severely occluded carotid disease and evidence of ipsilateral abnormal brain perfusion, but longer-term data is lacking. Taiwanese researchers studied 88 patients admitted for CAS and tracked their outcomes out to one year. They found patients with reduced brain blood flow (abnormal ipsilateral cerebral perfusion) at baseline, in whom carotid stenting was successful (n=49), showed improvements in a range of mental and cognitive tests at both 3 months and 1 year. By contrast, no such improvement was seen among patients in whom carotid stenting failed (n=8), nor in patients with successful carotid stenting who did not have abnormal ipsilateral cerebral perfusion before their procedures (n=29). The findings suggest that neurocognitive improvement following carotid artery stenting depends heavily on the presence of cerebral hypoperfusion at baseline as well as a successful procedure, and the cognitive benefit could be persistent up to 1 year.
Contact: Dr. Mao-Shin Lin, National Taiwan University Hospital, Taipei, TAIWAN email@example.com
Date: Friday May 22, 12:33, Room: 242A
Notes to Editors
Further information on press registration may be found at http://www.europcr.com/page/press/619-press.html
What is EuroPCR?
EuroPCR, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology, is the world-leading course in interventional medicine. PCR has established a distinctive format for educational activities in the field of cardiovascular interventions. Beyond its flagship course in Paris that gathers more than 12,000 participants every year, PCR organises annual courses in Singapore; London, UK; Dubai, EAU; Johannesburg, RSA; Istanbul, Turkey; Chengdu, China; and Tokyo, Japan.
For further information on EuroPCR, AsiaPCR/SingLIVE, PCR London Valves, GulfPCR-GIM, AfricaPCR, PCR Istanbul Peripheral, PCR-CIT China Chengdu Valves, PCR Tokyo Valves & PCR, please contact: Anne-Sophie Lartigau at firstname.lastname@example.org.
For more information, please visit http://www.europcr.com
For more information on the abstracts featured in this press release, please contact Isabelle Uzielli, email: email@example.com
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved